Market Cap (In USD)
7769.00
Revenue (In USD)
939.17 Thousand
Net Income (In USD)
-6.06 Million
Avg. Volume
38.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-4-0.0072
- PE
- -
- EPS
- -
- Beta Value
- -13.757
- ISIN
- CA05382F2026
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. G. F. Kym Anthony
- Employee Count
- -
- Website
- https://www.avivagen.com
- Ipo Date
- 2013-05-02
- Details
- Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
More Stocks
-
HG
-
3684
-
6901Diamond Biofund Inc.
6901
-
NITON2OFF, Inc.
NITO
-
3476MIRAI Corporation
3476
-
ZOO
-
CLBK
-
FAAFabasoft AG
FAA